




Instance: composition-en-fe68e84ae2a5a5a43e0a98992e2c4775
InstanceOf: CompositionUvEpi
Title: "Composition for doptelet Package Leaflet"
Description:  "Composition for doptelet Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpfe68e84ae2a5a5a43e0a98992e2c4775)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - doptelet"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Doptelet is and what it is used for  </li>
<li>What you need to know before you take Doptelet  </li>
<li>How to take Doptelet  </li>
<li>Possible side effects  </li>
<li>How to store Doptelet  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What doptelet is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What doptelet is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Doptelet contains an active substance called avatrombopag. It belongs to a group of medicines called 
thrombopoietin receptor agonists. </p>
<p>Doptelet is used in adults with chronic liver disease to treat low platelet count (called 
thrombocytopenia) before having a medical procedure where there is a risk of bleeding. </p>
<p>Doptelet is used to treat adults with low platelet counts due to primary chronic immune 
thrombocytopenia (ITP) when a prior treatment for ITP (such as corticosteroids or immunoglobulins) 
has not worked well enough. 
Doptelet works by helping to increase the number of platelets in the blood. Platelets are blood cells 
that help the blood to clot and so reduce or prevent bleeding. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take doptelet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take doptelet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Doptelet<br />
- if you are allergic to avatrombopag or any of the other ingredients of this medicine (listed in 
section 6). If you are not sure, talk to your doctor or pharmacist before taking Doptelet. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Doptelet if: 
* you are at risk of blood clots in your veins or arteries, or members of your family have had 
blood clots.<br />
* you have another blood condition known as myelodysplastic syndrome (MDS); taking Doptelet 
may worsen MDS.  </p>
<p>You may be at higher risk of blood clots as you get older or if:</p>
<ul>
<li>you have had to stay in bed for a long time </li>
<li>you have cancer </li>
<li>you are taking the contraceptive birth control pill or hormone replacement therapy </li>
<li>you have recently had surgery or been injured </li>
<li>you are very overweight </li>
<li>you smoke  </li>
<li>you have advanced chronic liver disease. </li>
</ul>
<p>If any of the above applies to you, or you are not sure, talk to your doctor or pharmacist before taking 
Doptelet. </p>
<p>Blood tests for platelet count 
If you stop taking Doptelet, your platelet count is likely to become low as before treatment or even 
lower, with a risk of bleeding. This may happen within days. The platelet count will be monitored, and 
your doctor will discuss appropriate precautions with you. </p>
<p>Tests to check your bone marrow 
In people who have problems with their bone marrow, medicines like Doptelet could make the 
problems worse. Signs of bone marrow changes may show up as abnormal results in your blood tests. 
Your doctor may also carry out a test to directly check your bone marrow during treatment with 
Doptelet. </p>
<p>Children and adolescents 
Do not give Doptelet to people less than 18 years old. The safety and effectiveness of this medicine in 
this age group is not known. </p>
<p>Other medicines and Doptelet<br />
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>If you are taking other medicines for ITP, you may need to take a lower dose or to stop taking them 
while you are taking Doptelet. </p>
<p>Pregnancy and breast-feeding<br />
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or 
pharmacist for advice before taking this medicine. Doptelet is not recommended in pregnancy and in 
women who are able to have children and are not using contraception. </p>
<p>If you are breast-feeding, ask your doctor or pharmacist for advice before taking Doptelet. This 
medicine can pass into breast milk. Your doctor will help you decide whether the benefit of 
breast-feeding outweighs any possible risks to your baby while you are breast-feeding. </p>
<p>Driving and using machines 
Doptelet is not expected to affect you being able to drive, cycle or use tools or machines. </p>
<p>Doptelet contains lactose 
Doptelet contains lactose (a type of sugar). If you have been told by your doctor that you have an 
intolerance to some sugars, contact your doctor before taking this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take doptelet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take doptelet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.  </p>
<p>If you have chronic liver disease and low platelet count you should be scheduled to undergo your 
procedure 5 to 8 days after the last dose of Doptelet. </p>
<p>If you have chronic ITP your doctor will tell you how much Doptelet to take and how often to take it. </p>
<p>How much to take  </p>
<p>If you have chronic liver disease and are scheduled for an invasive procedure 
* Doptelet is available in 20 mg tablets. The usual recommended dose is either 40 mg (2 tablets) 
or 60 mg (3 tablets) every day for 5 days in a row. 
* Your dose will depend on your platelet counts. 
* Your doctor or pharmacist will tell you how many tablets to take and when to take them. </p>
<p>If you have chronic ITP 
* The usual recommended starting dose is 20 mg (1 tablet) a day. If you are taking certain other 
medicines you may need a different starting dose. 
* Your doctor or pharmacist will tell you how many tablets to take and when to take them. 
* Your doctor will monitor your platelet count regularly and will adjust your dose as needed. </p>
<p>Taking this medicine </p>
<ul>
<li>Swallow the tablets whole and take with food at the same time each day that you take Doptelet. </li>
</ul>
<p>If you have chronic liver disease and low platelet count 
* Start taking Doptelet 10 to 13 days before your planned medical procedure. 
* Your doctor or pharmacist will tell you how many tablets to take and when to take them. </p>
<p>If you have chronic ITP 
* Your doctor or pharmacist will tell you how many tablets to take and when to take them. </p>
<p>If you take more Doptelet than you should 
* Talk to a doctor or pharmacist straight away. </p>
<p>If you forget to take Doptelet 
* Take your missed dose as soon as you remember, then take your next dose at the usual time. 
* Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Doptelet 
Take Doptelet for as long as your doctor tells you. Do not stop taking Doptelet unless your doctor tells 
you to. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Tell your doctor or pharmacist if you notice any of the following side effects. </p>
<p>The following side effects have been reported to be associated with treatment with Doptelet in 
adult patients with chronic liver disease: </p>
<p>Common (may affect up to 1 in 10 people) 
* feeling tired </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* low red blood cell count (anaemia) 
* blood clot in the portal vein (blood vessel that carries blood to the liver from the intestines) 
which may result in upper abdominal pain or swelling 
* bone pain 
* muscle aches 
* fever </p>
<p>Not known (frequency cannot be estimated from the available data) 
* allergic reactions including swollen face, swollen tongue, and skin changes such as rash and 
itching </p>
<p>The following side effects have been reported to be associated with treatment with Doptelet in 
adult patients with primary chronic ITP: </p>
<p>Very common (may affect more than 1 in 10 people) 
* feeling tired 
* headache </p>
<p>Common (may affect up to 1 in 10 people) 
* back pain, muscle pain, joint pain, pain in arms or legs 
* discomfort or pain of bones, muscles, ligaments, tendons, and nerves 
* feeling sick (nausea), diarrhoea, vomiting, abdominal pain, digestive wind/gas 
* dizziness, head discomfort, migraine 
* decreased appetite 
* weakness 
* nose bleeds 
* skin rash, itching, acne, red spots on skin 
* feeling of tingling, prickling or numbness, commonly called  pins and needles<br />
* enlarged spleen 
* shortness of breath 
* elevated blood pressure 
* tendency to bruise or bleed (low platelets) </p>
<p>Common side effects that may show up in blood tests 
* increased fats (cholesterol, triglycerides) 
* increased or decreased blood sugar (glucose) 
* increased liver enzyme (alanine aminotransferase) 
* increased lactate dehydrogenase 
* increased gastrin 
* decreased number of red blood cells (anaemia) 
* increased or decreased number of platelets </p>
<p>Uncommon (may affect up to 1 in 100 people)<br />
* redness, swelling and pain of a vein caused by a blood clot 
* pain, swelling and tenderness in one of your legs (usually the calf) with warm skin in the 
affected area (signs of a blood clot in a deep vein) 
* blood clots in the veins which carry blood away from the brain 
* narrowing of the blood vessels (vasoconstriction) 
* sudden shortness of breath, especially when accompanied with sharp pain in the chest and/or 
rapid breathing, which could be signs of a blood clot in the lungs 
* blockage or narrowing of the vein that brings blood to the liver 
* stroke or mini-stroke 
* heart attack 
* irregular heartbeat 
* haemorrhoids 
* dilation of the rectal veins 
* inflammation (swelling) and infection of the nose, sinuses, throat, tonsils, or middle ear (upper 
respiratory tract infection) 
* scarring of the bone marrow 
* loss of water or body fluids (dehydration) 
* increased appetite, hunger 
* mood changes 
* abnormal thinking 
* changes in sense of taste, smell, hearing, vision 
* eye problems including irritation, discomfort, itching, swelling, tearing, sensitivity to light, 
blurred vision, vision impaired, loss of vision 
* ear pain 
* increased sensitivity to everyday sounds 
* coughing up blood 
* nasal congestion 
* abdominal pain, discomfort or swelling 
* constipation 
* belching 
* acid reflux 
* burning or stinging sensation in mouth 
* numbness of the mouth, swollen tongue, tongue problems 
* numbness 
* hair loss 
* boils 
* dry skin 
* dark purple spots on skin (blood leakage out of blood vessels, bruising) 
* excessive sweating 
* changes in skin color 
* itchy rash 
* skin irritation 
* abnormality of a joint 
* muscle cramps, muscle weakness 
* blood in urine 
* heavy menstrual period 
* nipple pain 
* chest pain 
* pain 
* swelling in legs or arms </p>
<p>Uncommon side effects that may show up in blood tests 
* bacteria in the blood 
* increased white blood cells 
* decreased iron in blood 
* increased liver enzyme (aspartate aminotransferase), abnormal liver tests </p>
<p>Not known (frequency cannot be estimated from the available data) 
* allergic reactions including swollen face, swollen tongue, and skin changes such as rash and 
itching </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store doptelet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store doptelet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and on each blister after 
 EXP . The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Doptelet contains<br />
- The active substance is avatrombopag. Each film-coated tablet contains avatrombopag maleate 
equivalent to 20 mg of avatrombopag. </p>
<ul>
<li>The other ingredients are: 
Tablet core: lactose monohydrate (see section 2  Doptelet contains lactose ); microcrystalline 
cellulose [E460(i)]; crospovidone type B [E1202]; silica, colloidal anhydrous [E551]; 
magnesium stearate [E470b]. 
Film coating: poly(vinyl alcohol) [E1203]; talc [E553b]; macrogol 3350 [E1521]; titanium 
dioxide [E171]; iron oxide yellow [E172]. </li>
</ul>
<p>What Doptelet looks like and contents of the pack 
Doptelet 20 mg film-coated tablets (tablets) are pale yellow, round, rounded on the upper and lower 
side, marked with  AVA  imprinted on one side and  20  on the other. </p>
<p>The tablets are supplied in cartons containing one or two aluminium blisters. Each blister contains 
either 10 or 15 tablets.  </p>
<p>Marketing Authorisation Holder 
Swedish Orphan Biovitrum AB (publ) 
SE-112 76 Stockholm<br />
Sweden </p>
<p>Manufacturer 
Swedish Orphan Biovitrum AB (publ) 
Strandbergsgatan 49, 
Stockholm, 
SE-112 Sweden </p>
<p>This leaflet was last revised in . </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-fe68e84ae2a5a5a43e0a98992e2c4775
InstanceOf: CompositionUvEpi
Title: "Composition for doptelet Package Leaflet"
Description:  "Composition for doptelet Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpfe68e84ae2a5a5a43e0a98992e2c4775)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - doptelet"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at tage Doptelet  </li>
<li>Sådan skal du tage Doptelet  </li>
<li>Bivirkninger  </li>
<li>Opbevaring  </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What doptelet is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What doptelet is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Doptelet indeholder et aktivt stof, der kaldes avatrombopag. Det tilhører en gruppe lægemidler, der 
kaldes trombopoietin-receptor-agonister. </p>
<p>Doptelet bruges til voksne med kronisk leversygdom til at behandle et lavt antal blodplader (lavt 
trombocyttal, trombocytopeni), inden de skal have udført et indgreb, hvor der er risiko for blødning. </p>
<p>Doptelet bruges til at behandle voksne med lavt antal blodplader på grund af kronisk primær immun 
trombocytopeni (ITP), når en tidligere behandling af ITP (f.eks. kortikosteroider eller 
immunoglobuliner) ikke har virket godt nok. 
Doptelet virker ved at hjælpe med at øge antallet af blodplader i blodet. Blodplader er blodlegemer, 
som hjælper blodet med at størkne og dermed mindsker eller forebygger blødning. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take doptelet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take doptelet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Doptelet 
- hvis du er allergisk over for avatrombopag eller et af de øvrige indholdsstoffer i dette 
lægemiddel (angivet i afsnit 6). Tal med lægen eller apotekspersonalet, inden du tager Doptelet, 
hvis du er i tvivl. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Doptelet, hvis:</p>
<ul>
<li>du har risiko for blodpropper i dine blodårer, eller hvis nogen i din familie har haft en blodprop </li>
<li>du har en anden blodsygdom, kendt som myelodysplastisk syndrom (MDS). Hvis du tager 
Doptelet, kan det forværre MDS. </li>
</ul>
<p>Du kan have højere risiko for at få blodpropper med alderen, eller hvis:</p>
<ul>
<li>du har været sengeliggende igennem længere tid </li>
<li>du har kræft </li>
<li>du tager p-piller eller får hormonbehandling </li>
<li>du er blevet opereret eller er kommet til skade for nylig </li>
<li>du er meget overvægtig </li>
<li>du ryger </li>
<li>du har fremskreden, kronisk leversygdom. </li>
</ul>
<p>Tal med lægen eller apotekspersonalet, inden du tager Doptelet, hvis noget af ovenstående gælder for 
dig, eller hvis du er i tvivl. </p>
<p>Blodprøver til måling af antal blodplader 
Hvis du stopper med at tage Doptelet, vil dit antal blodplader sandsynligvis blive lavere, som før 
behandlingen eller endda lavere, med risiko for blødning. Dette kan ske i løbet af nogle dage. Antallet 
af blodplader vil blive overvåget, og lægen vil tale med dig om passende forholdsregler. </p>
<p>Prøver til kontrol af din knoglemarv 
Hos personer, som har problemer med knoglemarven, kan lægemidler som Doptelet forværre 
problemerne. Tegn på ændringer i knoglemarven kan konstateres som unormale resultater i dine 
blodprøver. Lægen vil muligvis også tage en direkte prøve af din knoglemarv under behandlingen med 
Doptelet. </p>
<p>Børn og unge 
Doptelet må ikke gives til personer under 18 år. Dette lægemiddels sikkerhed og virkning hos personer 
i denne aldersgruppe kendes ikke. </p>
<p>Brug af andre lægemidler sammen med Doptelet 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget 
andre lægemidler eller planlægger at tage andre lægemidler. </p>
<p>Hvis du tager andre lægemidler mod ITP, skal du muligvis tage en lavere dosis eller stoppe med at 
tage dem, mens du tager Doptelet. </p>
<p>Graviditet og amning<br />
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge 
din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. Doptelet frarådes under 
graviditeten og til kvinder, som kan blive gravide, og som ikke bruger prævention. </p>
<p>Hvis du ammer, skal du spørge lægen eller apotekspersonalet til råds, inden du tager Doptelet. Dette 
lægemiddel kan passere over i modermælken. Din læge vil hjælpe dig med at beslutte, om fordelene 
ved amning opvejer eventuelle risici for dit barn, mens du ammer. </p>
<p>Trafik- og arbejdssikkerhed 
Doptelet forventes ikke at påvirke din evne til at føre motorkøretøj eller cykel eller til at bruge værktøj 
og maskiner. </p>
<p>Doptelet indeholder lactose 
Doptelet indeholder lactose (en type sukker). Kontakt lægen, før du tager dette lægemiddel, hvis lægen 
har fortalt dig, at du ikke tåler visse sukkerarter. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take doptelet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take doptelet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet.  </p>
<p>Hvis du har kronisk leversygdom og et lavt antal blodplader, skal dit indgreb være planlagt til at blive 
udført 5 til8 dage efter den sidste dosis Doptelet. </p>
<p>Hvis du har kronisk ITP, vil lægen fortælle dig, hvor meget Doptelet du skal tage, og hvor ofte du skal 
tage det. </p>
<p>Så meget skal du tage </p>
<p>Hvis du har kronisk leversygdom og dit invasive indgreb er planlagt </p>
<ul>
<li>
<p>Doptelet fås i 20 mg tabletter. Den sædvanlige anbefalede dosis er enten 40 mg (2 tabletter) 
eller 60 mg (3 tabletter) hver dag i 5 dage i træk. </p>
</li>
<li>
<p>Din dosis afhænger af antallet af blodplader i dit blod (dit trombocyttal). </p>
</li>
<li>
<p>Lægen eller apotekspersonalet vil fortælle dig, hvor mange tabletter du skal tage, og hvornår du 
skal tage dem. </p>
</li>
</ul>
<p>Hvis du har kronisk ITP </p>
<ul>
<li>
<p>Den sædvanlige anbefalede startdosis er 20 mg (1 tablet) om dagen. Hvis du tager visse andre 
lægemidler, skal du muligvis have en anden startdosis. </p>
</li>
<li>
<p>Lægen eller apotekspersonalet vil fortælle dig, hvor mange tabletter du skal tage, og hvornår du 
skal tage dem. </p>
</li>
<li>
<p>Lægen vil regelmæssigt overvåge dit antal blodplader og justere din dosis efter behov. </p>
</li>
</ul>
<p>Indtagelse af lægemidlet </p>
<ul>
<li>Tabletterne skal synkes hele og tages sammen med mad på samme tidspunkt hver dag, du tager 
Doptelet. </li>
</ul>
<p>Hvis du har kronisk leversygdom og et lavt antal blodplader </p>
<ul>
<li>
<p>Begynd at tage Doptelet 10 til 13 dage før dit planlagte medicinske indgreb. </p>
</li>
<li>
<p>Din læge eller apotekspersonalet vil fortælle dig, hvor mange tabletter du skal tage, og hvornår 
du skal tage dem. </p>
</li>
</ul>
<p>Hvis du har kronisk ITP </p>
<ul>
<li>Din læge eller apotekspersonalet vil fortælle dig, hvor mange tabletter du skal tage, og hvornår 
du skal tage dem. </li>
</ul>
<p>Hvis du har taget for meget Doptelet </p>
<ul>
<li>Tal med en læge eller apotekspersonalet med det samme. </li>
</ul>
<p>Hvis du har glemt at tage Doptelet </p>
<ul>
<li>
<p>Tag den glemte dosis, så snart du kommer i tanke om det, og tag derefter den næste dosis på det 
sædvanlige tidspunkt. </p>
</li>
<li>
<p>Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
</li>
</ul>
<p>Hvis du holder op med at tage Doptelet 
Du skal tage Doptelet så længe, som din læge har fortalt dig. Du må ikke holde op med at tage 
Doptelet, medmindre lægen beder dig om det. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Fortæl det til lægen eller apotekspersonalet, hvis du får en eller flere af følgende bivirkninger. </p>
<p>De følgende bivirkninger er rapporteret at være forbundet med behandling med Doptelet hos 
voksne patienter med kronisk leversygdom: </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>træthed </li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>
<p>lavt antal røde blodlegemer (blodmangel/anæmi) </p>
</li>
<li>
<p>blodprop i portvenen (et blodkar, der fører blod til leveren fra tarmene), hvilket kan medføre 
smerter eller hævelser i den øverste del af maven </p>
</li>
<li>
<p>knoglesmerter </p>
</li>
<li>
<p>muskelømhed </p>
</li>
<li>
<p>feber. </p>
</li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke beregnes ud fra tilgængelige data) </p>
<ul>
<li>allergiske reaktioner, herunder hævet ansigt, hævet tunge og hudændringer, såsom udslæt og 
kløe </li>
</ul>
<p>De følgende bivirkninger er rapporteret at være forbundet med behandling med Doptelet hos 
voksne patienter med kronisk primær ITP: </p>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer) </p>
<ul>
<li>
<p>træthed </p>
</li>
<li>
<p>hovedpine </p>
</li>
</ul>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>rygsmerter, muskelsmerter, ledsmerter, smerter i arme eller ben </p>
</li>
<li>
<p>ubehag eller smerter i knogler, muskler, ledbånd, sener og nerver </p>
</li>
<li>
<p>kvalme, diarré, opkastning, mavesmerter, luft i maven </p>
</li>
<li>
<p>svimmelhed, ubehag i hovedet, migræne </p>
</li>
<li>
<p>nedsat appetit </p>
</li>
<li>
<p>svaghed </p>
</li>
<li>
<p>næseblødninger </p>
</li>
<li>
<p>hududslæt, kløe, akne, røde pletter på huden </p>
</li>
<li>
<p>brændende, prikkende eller følelsesløs fornemmelse, ofte kaldet en “sovende fornemmelse" </p>
</li>
<li>
<p>forstørret milt </p>
</li>
<li>
<p>åndenød </p>
</li>
<li>
<p>forhøjet blodtryk </p>
</li>
<li>
<p>tendens til blå mærker eller blødning (lavt antal blodplader) </p>
</li>
</ul>
<p>Almindelige bivirkninger, der kan konstateres i blodprøver </p>
<ul>
<li>
<p>forhøjede fedtstoffer (kolesterol, triglycerider) </p>
</li>
<li>
<p>forhøjet eller nedsat blodsukker (glucose) </p>
</li>
<li>
<p>forhøjet leverenzym (alaninaminotransferase) </p>
</li>
<li>
<p>forhøjet lactatdehydrogenase </p>
</li>
<li>
<p>forhøjet gastrin </p>
</li>
<li>
<p>nedsat antal røde blodlegemer (anæmi) </p>
</li>
<li>
<p>forhøjet eller nedsat antal blodplader </p>
</li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>
<p>rødme, hævelse og smerter i en vene forårsaget af en blodprop </p>
</li>
<li>
<p>smerter, hævelse og ømhed i et af dine ben (sædvanligvis læggen) med varm hud i det berørte 
område (tegn på en blodprop i en dyb vene) </p>
</li>
<li>
<p>blodpropper i de vener, som fører blodet væk fra hjernen </p>
</li>
<li>
<p>indsnævring af blodkarrene (vasokonstriktion) </p>
</li>
<li>
<p>pludselig åndenød, især når den ledsages af stærk smerte i brystkassen og/eller hurtig 
vejrtrækning, som kan være tegn på en blodprop i lungerne </p>
</li>
<li>
<p>blokering eller indsnævring af venen, der fører blod til leveren </p>
</li>
<li>
<p>slagtilfælde eller mildt slagtilfælde </p>
</li>
<li>
<p>hjerteanfald </p>
</li>
<li>
<p>uregelmæssige hjerteslag </p>
</li>
<li>
<p>hæmorider </p>
</li>
<li>
<p>udvidelse af rektale vener </p>
</li>
<li>
<p>inflammation (hævelse) og infektion i næse, bihuler, hals, mandler eller mellemøre (øvre 
luftvejsinfektion) </p>
</li>
<li>
<p>ardannelse i knoglemarven </p>
</li>
<li>
<p>tab af vand eller legemsvæsker (dehydrering) </p>
</li>
<li>
<p>øget appetit, sult </p>
</li>
<li>
<p>humørudsving </p>
</li>
<li>
<p>unormal tankegang </p>
</li>
<li>
<p>ændringer i smags- og lugtesans, hørelse, syn </p>
</li>
<li>
<p>øjenproblemer, herunder irritation, ubehag, kløe, hævelse, tåreflod, lysfølsomhed, sløret syn, 
nedsat syn, synstab </p>
</li>
<li>
<p>ørepine </p>
</li>
<li>
<p>øget følsomhed over for hverdagslyde </p>
</li>
<li>
<p>ophostning af blod </p>
</li>
<li>
<p>tilstoppet næse </p>
</li>
<li>
<p>smerter, besvær eller oppustning af mave </p>
</li>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>opstød </p>
</li>
<li>
<p>syrerefluks </p>
</li>
<li>
<p>brændende eller sviende fornemmelse i munden </p>
</li>
<li>
<p>følelsesløshed i munden, hævet tunge, tungeproblemer </p>
</li>
<li>
<p>følelsesløshed </p>
</li>
<li>
<p>hårtab </p>
</li>
<li>
<p>bylder </p>
</li>
<li>
<p>tør hud </p>
</li>
<li>
<p>mørkelilla pletter på huden (udsivning af blod fra blodkar, blå mærker) </p>
</li>
<li>
<p>overdreven svedtendens </p>
</li>
<li>
<p>ændringer i hudfarve </p>
</li>
<li>
<p>kløende udslæt </p>
</li>
<li>
<p>hudirritation </p>
</li>
<li>
<p>unormalt led </p>
</li>
<li>
<p>muskelkramper, muskelsvaghed </p>
</li>
<li>
<p>blod i urinen </p>
</li>
<li>
<p>kraftig menstruation </p>
</li>
<li>
<p>smerter i brystvorterne </p>
</li>
<li>
<p>brystsmerter </p>
</li>
<li>
<p>smerter </p>
</li>
<li>
<p>hævede ben eller arme </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger der kan konstateres i blodprøver </p>
<ul>
<li>
<p>bakterier i blodet </p>
</li>
<li>
<p>forhøjet antal hvide blodlegemer </p>
</li>
<li>
<p>nedsat jern i blodet </p>
</li>
<li>
<p>forhøjet leverenzym (aspartataminotransferase), unormale leverprøver </p>
</li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke beregnes ud fra tilgængeligedata) </p>
<ul>
<li>allergiske reaktioner, herunder hævet ansigt, hævet tunge og hudændringer, såsom udslæt og 
kløe </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store doptelet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store doptelet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Tag ikke lægemidlet efter den udløbsdato, der står på pakningen og hvert blisterkort efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du ikke 
smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Doptelet indeholder:</p>
<ul>
<li>
<p>Aktivt stof: avatrombopag. En filmovertrukket tablet indeholder avatrombopagmaleat svarende 
til 20 mg avatrombopag. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: 
Tabletkerne: lactosemonohydrat (se afsnit 2, "Doptelet indeholder lactose"); mikrokrystallinsk 
cellulose [E460(i)]; crospovidon type B [E1202]; silica, kolloid vandfri [E551]; 
magnesiumstearat [E470b]. 
Filmovertræk: polyvinylalkohol [E1203]; talcum [E553b]; macrogol 3350 [E1521]; titandioxid 
[E171]; gul jernoxid [E172]. </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Doptelet 20 mg filmovertrukne tabletter (tabletter) er bleggule, runde tabletter, som buer ud foran og 
bagpå og har "AVA" trykt på den ene side og "20" på den anden. </p>
<p>Tabletterne udleveres i æsker med én eller to aluminiumsblisters. En blister indeholder enten 
10 eller 15 tabletter. </p>
<p>Indehaver af markedsføringstilladelsen 
Swedish Orphan Biovitrum AB (publ) 
SE-112 76 Stockholm 
Sverige </p>
<p>Fremstiller 
Swedish Orphan Biovitrum AB (publ) 
Strandbergsgatan Stockholm 
SE-112 Sverige </p>
<p>Denne indlægsseddel blev senest ændret . </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-fe68e84ae2a5a5a43e0a98992e2c4775
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for doptelet Package Leaflet for language en"
Description: "ePI document Bundle for doptelet Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-fe68e84ae2a5a5a43e0a98992e2c4775"
* entry[0].resource = composition-en-fe68e84ae2a5a5a43e0a98992e2c4775

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpfe68e84ae2a5a5a43e0a98992e2c4775"
* entry[=].resource = mpfe68e84ae2a5a5a43e0a98992e2c4775
                            
                    
Instance: bundlepackageleaflet-da-fe68e84ae2a5a5a43e0a98992e2c4775
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for doptelet Package Leaflet for language da"
Description: "ePI document Bundle for doptelet Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-fe68e84ae2a5a5a43e0a98992e2c4775"
* entry[0].resource = composition-da-fe68e84ae2a5a5a43e0a98992e2c4775

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpfe68e84ae2a5a5a43e0a98992e2c4775"
* entry[=].resource = mpfe68e84ae2a5a5a43e0a98992e2c4775
                            
                    



Instance: mpfe68e84ae2a5a5a43e0a98992e2c4775
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Doptelet 20 mg film-coated tablets"
Description: "Doptelet 20 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/19/1373/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Doptelet 20 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: fe68e84ae2a5a5a43e0a98992e2c4775ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "doptelet"

* status = #current
* mode = #working

* title = "List of all ePIs associated with doptelet"

* subject = Reference(mpfe68e84ae2a5a5a43e0a98992e2c4775)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#doptelet "doptelet"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-fe68e84ae2a5a5a43e0a98992e2c4775) // doptelet en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-fe68e84ae2a5a5a43e0a98992e2c4775) // doptelet da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-fe68e84ae2a5a5a43e0a98992e2c4775
InstanceOf: List

* insert fe68e84ae2a5a5a43e0a98992e2c4775ListRuleset
    